trending Market Intelligence /marketintelligence/en/news-insights/trending/fvOsa2pZEN-cKqUhB16C1g2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Non-opioid pain management drugmakers Scilex, Semnur to merge

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Non-opioid pain management drugmakers Scilex, Semnur to merge

Sorrento Therapeutics Inc. unit SCILEX Pharmaceuticals Inc. will merge with fellow pain management drug developer Semnur Pharmaceuticals Inc., Sorrento said March 22.

The merger will form a new company called Scilex Holding Co., in which Sorrento will now hold a 58% equity stake.

Both the California-based drugmakers develop non-opioids for pain. Scilex's ZTlido is a lidocaine topical patch and received U.S. Food and Drug Administration approval for post-shingles pain in February 2018. Semnur's non-opioid corticosteroid gel injection, SP102, for a type of spinal pain, is currently in phase 3 trials.

Semnur CEO Jaisim Shah will become the CEO of the newly formed Scilex Holding, Sorrento's press release stated.

"This transaction is highly synergistic," Sorrento CEO and Chairman Henry Ji said. "Scilex has built up a commercial organization ... while Semnur has a very exciting phase 3 compound ... Sorrento is now well-positioned to address an approximately $63 billion pain therapeutics market."